Relmada Therapeutics, Inc.
RLMD
$0.3644
-$0.0339-8.51%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -22.86% | -14.25% | -5.66% | -1.38% | 2.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.10% | -20.71% | -30.61% | -34.79% | -35.69% |
| Operating Income | 19.10% | 20.71% | 30.61% | 34.79% | 35.69% |
| Income Before Tax | 19.04% | 22.48% | 32.74% | 34.34% | 37.09% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 19.04% | 22.48% | 32.74% | 34.34% | 37.09% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 19.04% | 22.48% | 32.74% | 34.34% | 37.09% |
| EBIT | 19.10% | 20.71% | 30.61% | 34.79% | 35.69% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 19.22% | 22.59% | 32.81% | 34.47% | 38.13% |
| Normalized Basic EPS | 18.63% | 20.96% | 31.84% | 36.75% | 38.85% |
| EPS Diluted | 19.18% | 22.59% | 32.80% | 34.49% | 38.15% |
| Normalized Diluted EPS | 18.63% | 20.96% | 31.84% | 36.75% | 38.85% |
| Average Basic Shares Outstanding | 0.21% | 0.15% | 0.12% | 0.19% | 1.60% |
| Average Diluted Shares Outstanding | 0.21% | 0.15% | 0.12% | 0.19% | 1.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |